Gloomy Neuroscience Partnering Outlook May Soon Brighten
At least two companies in the neuroscience space are set to deliver potentially good news by year’s end, with other promising candidates in the offing, according to industry consultant Harry Tracy, who compiled a list of the top 10 partnering opportunities in the field for the upcoming Therapeutic Area Partnerships meeting.
You may also be interested in...
The Maryland CNS company got an FDA approval for its second epilepsy product and will begin marketing the drug before the close of the third quarter.
“Everything that applies to pharma in general is magnified in neuroscience because the timelines are compressed and the punishment for failure is greater,” industry consultant Harry Tracy said at the Therapeutic Area Partnerships meeting.
Johnson & Johnson executives including Pharma Chairman and CSO Paul Stoffels explain how building a presence in innovation’s backyard will allow the health care giant to more easily and quickly access new assets and technologies. Can proximity to innovation make J&J more innovative?